Meningococcal vaccine

What is meningococcal conjugate vaccine? Meningococcal disease is a Meningococcal disease spreads from person to person through small droplets of saliva expelled into the air when an infected person coughs or sneezes. The bacteria is usually passed through close contact with an infected person, especially through kissing or sharing a drinking glass or eating utensil. Meningococcal conjugate vaccine is used to prevent The Like any vaccine, meningococcal conjugate vaccine may not provide protection from disease in every person. Before taking this medicine You may not be able to receive this vaccine if you've ever had an allergic reaction to a meningococcal, This vaccine may need to be postponed or not given at all if you have: • a severe illness with a • a weak immune system caused by disease or by using certain medicine (this vaccine may not be as effective if you are immunosuppressed); • a history of Guillain-Barré syndrome; or • a history of premature birth. You can still receive a vaccine if you've a minor cold. Your doctor should determine whether you need this vaccine during pregnancy or while breastfeeding. How is this vaccine given? This vaccine is given as an injection (shot) into a muscle. You will receive this injection in a doctor's office or clinic setting. Meningococcal conjugate vaccine is recommended if: • you've been exposed to an outbreak of meningococcal disease; • you are in the military; • you work in a laboratory and are exposed to meningococcal bacteri...

Based on emerging data on live-attenuated and inactivated vaccines, the American Society of Transplantation Infectious Diseases Community of Practice (AST IDCOP) released updated recommendations for the vaccination of solid organ transplant candidates and recipients. This report was published in Clinical Transplantation. Recommendations for General Principles Prior to transplantation, all transplant candidates and their household members should have completed the full complement of recommended vaccinations; vaccination status should be reviewed upon first visit and a vaccine strategy should be developed. Inactivated vaccines should be administered 2 weeks prior to transplantation, while live-attenuated vaccines should be administered at least 4 weeks before organ transplant. If vaccination was not completed prior to transplantation, recommendations by national immunization advisory committees suggest that inactivated vaccines are safe following solid organ transplantation. Post-transplant, live vaccines are not advised, but inactivated vaccines may be administered 3 to 6 months after transplantation, with the exception of the influenza vaccine, which can be administered 1-month post-transplant. Healthcare workers, family members, close contacts, and the pets of transplant candidates should be fully immunized. These individuals should receive a yearly influenza vaccine, preferably the inactivated The AST IDCOP strongly recommends influenza vaccination for all transplant can...

The meningococcal vaccines protect against meningococcal disease, which can lead to bacterial Two kinds of meningococcal (meh-nin-guh-KOK-uhl) vaccines are currently given to kids in the United States: • The meningococcal conjugate vaccine (MenACWY) protects against four types of meningococcal bacteria (types A, C, W, and Y). It is recommended for all kids and teens age 11 and older. Some types of MenACWY are given to younger children (as early as 8 weeks of age) if they have a higher risk of getting meningococcal disease. • The meningococcal B vaccine (MenB) protects against a fifth type of meningococcal bacterium (called type B). It is fairly new and not yet recommended as a routine vaccination for healthy people.But some kids and teens who are at increased risk for meningococcal disease should get it starting from age 10. Others who are not at increased risk may also get it between the ages of 16 and 23 (preferably between 16 through 18 as that is when the risk of getting infected is highest). The decision to get the MenB vaccine is made by the teen, their parents, and their doctor. When Are Meningococcal Vaccines Given? Vaccination withMenACWY is recommended: • when kids are 11 or 12 years old, with a booster given at age 16 • for teens 13–18 years old who haven't been vaccinated yet Those who have their first dose between the ages of 13–15 should get a booster dose between the ages of 16–18. Teens who get their first dose after age 16 won't need a booster dose. Kids a...

Other studies also noted a large drop in meningococcal disease since the vaccine was introduced. One 2020 paper in JAMA Pediatrics analyzed the national rates of meningococcal disease between 2000 and 2005 (pre-vaccine recommendation) and compared it to 2011 to 2017 (after the CDC implemented a vaccination recommendation). The annual incidence rates of three strains (C, W, and Y) of meningococcal disease were already dropping in the pre-vaccine period by about 14.6% among adolescents 16 to 22 years old. But that drop accelerated after vaccine introduction. Between 2011 and 2017, the incidence of meningitis due to these strains dropped by 35.6% per year. A study compared meningococcal disease cases and deaths in the Republic of Korea Armed Forces between 2008 and 2013 (before a meningococcal vaccine became obligatory) and 2013 to 2016 (after an obligatory vaccine). Data showed the MenACWY vaccine is 88% effective in protecting against meningococcal disease. As for MenB vaccines, the CDC notes that there have been no randomized controlled trials evaluating this vaccine's safety for pregnant or lactating people. The agency suggests that vaccination can wait until after this period. But if the person is at increased risk of meningococcal disease, a vaccine should still be considered. • Have a rare immune disorder called complement component deficiency • Are taking a complement inhibitor medication like Soliris (eculizumab) or Ultomiris(ravulizumab) • Have a damaged • Are trave...

• العربية • تۆرکجه • বাংলা • Chi-Chewa • ChiShona • Ελληνικά • Español • فارسی • Français • 한국어 • Igbo • Bahasa Indonesia • עברית • Kiswahili • Lietuvių • Magyar • മലയാളം • मराठी • Bahasa Melayu • မြန်မာဘာသာ • 日本語 • ଓଡ଼ିଆ • ਪੰਜਾਬੀ • Português • Română • SiSwati • Suomi • தமிழ் • తెలుగు • ไทย • Tiếng Việt • Wolof • Yorùbá • 中文 • N Y Meningococcal vaccine refers to any The Meningococcal vaccines are generally safe. The first meningococcal vaccine became available in the 1970s. Inspired by the response to the 1997 outbreak in Nigeria, the WHO, Types [ ] Quadrivalent (serogroups A, C, W-135, and Y) [ ] There are three vaccines available in the United States to prevent meningococcal disease, all quadrivalent in nature, targeting serogroups A, C, W-135, and Y: • three Menveo and MenQuadfi are approved for medical use in the European Union. Menactra and Menveo [ ] The first meningococcal conjugate vaccine (MCV-4), Menactra, was licensed in the U.S. in 2005 by Menquadfi [ ] Menquadfi, manufactured by Menomune [ ] Meningococcal polysaccharide vaccine (MPSV-4), Menomune, has been available since the 1970s. It may be used if MCV-4 is not available, and is the only meningococcal vaccine licensed for people older than 55. Information about who should receive the meningococcal vaccine is available from the CDC. Nimenrix [ ] Nimenrix (developed by GlaxoSmithKline and later acquired by Mencevax [ ] Mencevax ( Limitations [ ] The duration of immunity mediated by Menomune (MPSV-4) is three ...